AzTrials
AzTrials

HealthyNCT05986500

The GALAXY-1 Project

A study testing Galactose in people with Healthy, run by University of Aarhus at 1 site in Denmark.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

"The understanding of the two sugars, glucose and fructose, has been thoroughly investigated regarding their impact on human metabolism during exercise. The consumption of the sugar galactose is an intriguing alternative and can be beneficial, especially for individuals with type 1 Diabetes, as it reduces the need for… Read more about this study

Who is it for?
Ages 50 to 75 yearsHealthy volunteers can take part
Conditions the study is for
Healthy
What is being tested?
Galactose
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
8 participants
Where
1 siteDenmark
Study dates
12 Feb 2024to 31 May 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 50 to 75 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Age 50-75 years
  • Male or post-menopausal female
  • BMI 18.5-30 kg/m2

Who cannot join

  • Clinically significant heart, lung, kidney, kidney, liver, endocrine or malignant disease based on information obtained during an initial screening visit as well as blood samples
  • Blood donation within the last 3 months
  • Smoking
  • Alcohol- or substance abuse
  • Participation in other clinical trials involving ionizing radiation within the last 6 months
  • Claustrophobia
  • Not being physically able to exercise one leg for one hour

Trial locations and contacts

1 site in 1 country.

Thien V Luong, MD contact

+4531513750

thiluo@clin.au.dk

Esben Søndergaard, MD, PhD contact

esben.sondergaard@clin.au.dk

Denmark1 site, 1 recruiting
  • Aarhus University Hospital

    Aarhus N, Jutland, 8200

    Thien V Luong, MD, 31513750 ext. +45, thiluo@clin.au.dk

    Esben Søndergaard, MD, PhD, esben.sondergaard@clin.au.dk

    Recruiting

Other trials in Denmark

About this study

Official title: The GALAXY-1 Project: Galactose - the Ideal Carbohydrate Supplement for Exercise

"The understanding of the two sugars, glucose and fructose, has been thoroughly investigated regarding their impact on human metabolism during exercise. The consumption of the sugar galactose is an intriguing alternative and can be beneficial, especially for individuals with type 1 Diabetes, as it reduces the need for insulin to maintain normal blood sugar levels. Additionally, galactose oxidation rates during exercise are only 50-60% compared to glucose, primarily due to liver storage and/or the requirement for conversion to glucose in the liver before oxidation. This delay in metabolism can prevent hyperglycemia before exercise and provide extended protection against episodes of hypoglycemia during and after exercise through a moderate and prolonged glycemic response.

The purpose of this experiment is to investigate whether galactose is taken up by skeletal muscles and the heart in response to exercise or hyperinsulinemia. Using non-invasive 18F-FDGal PET, the investigators will examine this in a randomized controlled study design. The results could contribute to updating dietary recommendations, particularly for individuals with type 1 diabetes who struggle to maintain normal blood sugar levels during and after exercise."

Read the detailed description

It is generally accepted that saccharides have to be converted into glucose before they can be oxidized and used to produce energy. As a result, non-glucose saccharides affect blood glucose levels differently than glucose. For example, the saccharide fructose requires hepatic conversion to glucose, causing more constant blood sugar levels and less risk of both glucose excursions and hypoglycemia during exercise. However, metabolization of fructose increases the risk of developing nonalcoholic fatty liver disease due to the stimulation of de novo lipogenesis and blocking of β-fatty acid oxidation. Consequently, a different carbohydrate source with the same glycemic profile as fructose but without the undesirable hepatic effects would be preferable. Galactose is the third of the three quantitively important dietary monosaccharides in a regular Western diet. Lactose (disaccharide of galactose and glucose) from dairy products is the primary source of dietary galactose, but galactose is also found in other food sources such as fruits and vegetables. While the impact of glucose and fructose on human metabolism has been extensively studied, there is limited knowledge of the effects of galactose as a nutritional supplement during or before exercise, and it is also unknown whether it can have clinical applications.

Intake of galactose or lactose instead of glucose prior to exercise may be advantageous, particularly for individuals with diabetes, since it lowers the insulin requirement to maintain euglycemia. Furthermore, galactose oxidation rates during exercise are only 50-60% compared to glucose, presumably due to hepatic storage and/or a requirement for conversion to glucose in the liver before oxidation. This delay in end-point metabolism could prevent hyperglycemia prior to exercise and at the same time provide prolonged protection from hypoglycemia during and after exercise via the prolonged and moderated glycemic response. In line with this, a recent study from the investigators' collaborator Gareth Wallis's group showed that lactose ingestion in relation to exercise increased fat oxidation and lowered carbohydrate oxidation compared to sucrose ingestion. Accordingly, ingestion of the lactose component - galactose - instead of regular glucose-containing carbohydrates is an intriguing option if blood glucose excursions are to be avoided. However, it is still unclear whether the beneficial metabolic effects of galactose are all caused by the hepatic delay in conversion to glucose or if galactose is also used directly by skeletal muscle as a source of energy. To address this, the investigators recently performed positron emission tomography (PET) pilot studies in two pigs using the galactose analogue 18F-FDGal to measure insulin-stimulated skeletal and cardiac muscle galactose uptake. Although muscle galactose uptake was clearly less than for glucose, it was evident that some uptake can be stimulated by insulin, particularly in the heart. These preliminary data question the current perception that galactose requires conversion to glucose in the liver before it can be utilized as a source of energy. However, studies in anesthetized pigs obviously cannot determine whether a similar direct muscle uptake of galactose can be stimulated by exercise per se, as is the case for glucose.

Purpose:

The purpose of this experiment is to investigate whether galactose is: 1) taken up by skeletal muscle and extra-hepatic organs, 2) if galactose uptake is affected by prior high intensity exercise with the purpose of depleting glycogen in the working skeletal muscle, and 3) if and to what extent insulin stimulates galactose uptake.

Methods:

Eight healthy participants will be studied twice in randomized order with 18F-FDGal PET scans during saline infusion (study day 1), and during a hyperinsulinemic-euglycemic clamp (study day 2). To stimulate galactose uptake in the femoral skeletal muscles, each participant will perform a 60-minute one-legged exercise prior to the PET scan. The non-exercised leg will serve as a control to quantify exercise-stimulated galactose uptake (Figure 2). During each study day, participants will receive a galactose infusion (bolus: 6 mmol, infusion rate: 1 mmol/min) to mimic concentrations of galactose similar to what can be achieved after galactose ingestion (1-2 mmol/L) (10). This design allows the investigators to quantify both the independent and combined effects of insulin and exercise on galactose uptake in skeletal muscle.

Volunteers:

Inclusion criteria:

  1. Age 50-75 years
  2. Males or post-menopausal females
  3. BMI 18.5-30 kg/m2

Exclusion criteria:

  1. Clinically significant heart, lung, kidney, liver, endocrine, or malignant disease based on information obtained during an initial screening visit as well as blood samples
  2. Blood donation within the last 3 months
  3. Smoking
  4. Alcohol- or substance abuse
  5. Participation in other clinical trials involving ionizing radiation within the last 6 months
  6. Claustrophobia
  7. Not being physically able to exercise one leg for one hour
Conditions
Healthy
Being tested
Galactose, No intervention
Keywords
Galactose, Exercise, PET, Insulin
Medical subject headings
Motor Activity, Insulin Resistance

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • GalactoseOther

    The participants will receive a galactose infusion (bolus: 6 mmol, infusion rate: 1 mmol/min)

  • No interventionOther

    The participants will receive a saline infusion

Study groups in NCT05986500
Study groupRoleWhat they receive
GalactoseExperimentalThe participants will receive a galactose infusion
Receives: Other: Galactose
SalineExperimentalThe participants will receive a saline infusion
Receives: Other: No intervention

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Galactose uptake in skeletal muscle

    Skeletal muscle galactose uptake rate (μmol/min/g) measured by 2-(18)F-fluoro-2-deoxy-d-galactose (18F-FDGal)

    Measured: Measurements will be made on each of the two study days

Secondary outcomes (4)
  1. Cardiac galactose uptake

    Cardiac galactose uptake rate (μmol/min/g) measured by 2-(18)F-fluoro-2-deoxy-d-galactose (18F-FDGal)

    Measured: Measurements will be made on each of the two study days

  2. Hepatic galactose uptake

    Hepatic galactose uptake rate (μmol/min/g) measured by 2-(18)F-fluoro-2-deoxy-d-galactose (18F-FDGal)

    Measured: Measurements will be made on each of the two study days

  3. Plasma glucose levels

    Measured in blood samples

    Measured: Measurements will be made on a screening day and during each of the two study days

  4. Skeletal muscle arterio-venous galactose balance

    Differences in arterio-venous galactose concentrations taken through catheters in both vv. famoralis and a. radialis

    Measured: Measurements will be mader during each of the two study days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Aug 2023
  2. Study start12 Feb 2024
  3. Primary completion1 Nov 2024 (estimated)
  4. Study completion31 May 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Crossover
Masking
None (open label)
Enrolment
8 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05986500
Sponsor's protocol ID
1-10-72-49-23
Status last verified
Aug 2023
First submitted
3 Aug 2023
Last updated
23 Apr 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A study testing Galactose in people with Healthy, run by University of Aarhus at 1 site in Denmark.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 23 Apr 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Thien V Luong, MD (+4531513750, thiluo@clin.au.dk), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Galactose uptake in skeletal muscle (time frame: Measurements will be made on each of the two study days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Apr 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in